Previous 10 | Next 10 |
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Founder, Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong, M.D., will deliver a company presentation at the 2021 Jefferies London Healthcare Conferenc...
Primary endpoints were met for both Cohorts A and B of Carcinoma in Situ (CIS) and Papillary disease in the 154-patient Phase 2/3 trial studying Anktiva (N-803) and BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) In papillary disease, 57% of patients remain dise...
More than 50 participants in third-line cohort of QUILT 88 trial have received the Nant Cancer Vaccine, which includes ImmunityBio’s off-the-shelf, targeted natural killer cells (PD-L1 t-haNK), IL-15 receptor agonist Anktiva (N-803), and Aldoxorubicin, plus low-dose chemotherap...
ImmunityBio’s share price bearish trend continues since its merger despite Anktiva moving closer to a BLA submission in BCG-unresponsive non-muscle-invasive carcinoma in situ bladder cancer. This extensive sell-off is demoralizing and is inflicting max pain on longs. I believe ...
Lung-MAP trials are studying how well investigational or new drugs work in non-small cell lung cancer (NSCLC) patients and will study how N-803 (Anktiva) could bolster the current standard of care, checkpoint inhibitors. ImmunityBio’s study will test its IL-15 receptor supe...
58 out of 81 (72%) patients achieved a complete response at any time (three or six months), which compares favorably to historical complete response rates of 41% and 18% for FDA-approved therapies pembrolizumab and valrubicin, respectively Median duration of complete response in a...
Biopharma leaders bring proven market development talents in urology and oncology to bolster company’s commercialization plan and long-term growth plans Helen Luu, former CEO of Cell BT, is named ImmunityBio’s first Chief Commercial Officer and brings a strong ba...
ImmunityBio, Inc. (NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced Karim Chamie, M.D., Associate Professor of Urology, UCLA Department of Urology, will be presenting the Phase 2/3 clinical results of IL-15 Superagonist N-803 with BCG in BCG-unresponsive bladd...
The novel immunotherapy NANT Cancer Vaccine (NCV) developed at ImmunityBio based on the concept of founder Patrick Soon-Shiong, M.D. has been studied in both Phase 1 and 2 trials in tumor types including pancreatic, breast, colorectal, and head and neck cancers. The NCV is an inno...
The ImmunityBio and NantKwest merger has created a clinical powerhouse in immunotherapy. The share price continues to show weakness since the merger with little reaction to positive news. It is possible the market has lost sight of IBRX, despite several programs moving closer to the f...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...